Aslan out­li­cens­es atopic der­mati­tis an­ti­body in $138.5M deal

Aslan Phar­ma­ceu­ti­cals grant­ed ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights in Japan for an IL-13 an­ti­body to a Japan­ese drug­mak­er in a deal worth up to $138.5 mil­lion.

As part of the deal an­nounced Thurs­day, Zenyaku Ko­gyo, in ex­change for rights to the drug in atopic der­mati­tis and all oth­er in­di­ca­tions, will give Aslan $12 mil­lion up­front and an­oth­er $3 mil­lion once cer­tain con­di­tions are met from a Phase IIb tri­al read­out that is slat­ed for ear­ly Ju­ly. The place­bo-con­trolled tri­al is eval­u­at­ing eblasakimab in 300 bi­o­log­ic-naive pa­tients with mod­er­ate-to-se­vere atopic der­mati­tis over 16 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER